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Abstract
Cancer-related fatigue is serious and complex, as well as one of the most common symptoms experienced by patients
with colorectal cancer, with the potential to compromise quality of life, activities of daily living, and ultimately survival.
There is a lack of consensus about the definition of cancer-related fatigue; however, definitions have been put forward
by the European Association for Palliative Care (EAPC) and the National Comprehensive Cancer Network (NCCN).
Numerous cancer- and treatment-related factors can contribute to fatigue, including disease progression, comor-
bidities, medical complications such as anemia, side effects of other medications, and a number of physical and
psychologic factors. This underlines the importance of tackling factors that may contribute to fatigue before reducing
the dose of treatment. NCCN guidelines and the EAPC have proposed approaches to managing fatigue in cancer
patients; however, relatively few therapeutic agents have been demonstrated to reduce fatigue in randomized
controlled trials. It is recognized that physical activity produces many beneficial physiologic modifications to markers
of physical performance that can help to counteract various causes of fatigue. In appropriately managed and moni-
tored patients with colorectal cancer, emerging evidence indicates that exercise programs may have a favorable in-
fluence on cancer-related fatigue, quality of life, and clinical outcomes, and therefore may help patients tolerate
chemotherapy. This review assesses fatigue in patients with colorectal cancer and proposes updates to a treatment
algorithm that may help clinicians manage this common problem.
Clinical Colorectal Cancer, Vol. 16, No. 4, 275-85ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cancer management, Cancer-related fatigue, Colorectal cancer, Exercise, Quality of lifeIntroduction
Cancer-related fatigue is a serious, debilitating, and complex
symptom experienced by many patients1 that may compromise
quality of life (QoL), activities of daily living, and ultimately sur-
vival. Yet cancer-related fatigue is underrecognized and undertreated
by many physicians and caregivers. For example, clinicians were less
likely to report fatigue than their patients, while patients’ reports of
fatigue were more concordant with their health status score (assessed
by the Euro QoL EQ-5D instrument) compared to clinicians’ re-
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http://dx.doi.org/10.1016/j.clcc.2016.04.010fatigue is inadequately managed; reasons cited include a lack of
awareness regarding interventions, limited assessment knowledge,
and rating fatigue as a low priority. Barriers to optimal management
of fatigue may include a failure to consult guidelines or structured
tools.3 Recent studies offer new insights into the causes and con-
sequences of fatigue as well offering rational approaches to man-
agement, in which exercise is central. This review examines fatigue
in patients with colorectal cancer (CRC) and suggests an algorithm
to help clinicians manage this common problem.
Definition of Fatigue
Currently there is a lack of consensus on how cancer-related fatigue
should be defined; however, definitions have been put forward by the
European Association for Palliative Care (EAPC) and the National
Comprehensive Cancer Network (NCCN) in the United States.
The EAPC offers a working definition of cancer-related fatigue as
“a subjective feeling of tiredness, weakness or lack of energy.”4 The
NCCN defines cancer-related fatigue as “a distressing, persistent,
subjective sense of physical, emotional and/or cognitive tiredness or
exhaustion related to cancer or cancer treatment that is not propor-
tional to recent activity and interferes with usual function.”5BY-NC-ND license (http://creativecommons.org/
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Table 1 Percentage of Colorectal Cancer Patients in Epide-
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Table 2 Examples of Rates of Fatigue With Chemotherapy and
Targeted Treatments for Metastatic Colorectal Cancer
Regimen Line n Grade 3/4
Chemotherapy
FOLFIRI13 1 209 10%
FOLFOX-414 1 649 7.9%
XELOX14 1 655 5.2%
FOLFOX-415 2 308 8.8%
XELOX15 2 311 7.1%
Targeted Therapies
Aflibercept-FOLFIRI16 >1a 1226 <5% difference compared to




1 1401 Not cited in “adverse events
of special interest to
bevacizumab”
FLOX18 1 185 10%






2 1186 <5% difference compared to
FOLFIRI
Regorafenib20 >1 500 9.6% vs. 5.1% in placebo arm
(<5% difference)
Regorafenib21 >1 136 2.9% vs. 1.5% in placebo arm
(<5% difference)
Abbreviations: FLOX ¼ fluorouracil, leucovorin, oxaliplatin; FOLFIRI ¼ fluorouracil, leucovorin,




Approach to Fatigue ManagementIn clinical trials, the Common Terminology Criteria for Adverse
Events are used when identifying and grading adverse events associ-
ated with treatment.6 Fatigue (defined as asthenia, lethargy, and
malaise) is graded according to the effect on the patient’s daily living,
with grade 4 identified as disabling.6 These different definitions may
lead to ambiguity when recognizing cancer-related fatigue, and along
with potential cultural influences attributing varying importance to
this symptom, patients may continue to be undertreated.
It must be noted that discussion is still underway regarding the
multidimensional nature of fatigue, including how many di-
mensions may be involved. The existence of physical and mental
aspects of cancer-related fatigue appears to be generally agreed upon.
However, it remains to be seen whether fatigue is a single symptom
including multiple dimensions (including physical and mental) or
whether physical fatigue and mental fatigue are in fact distinct
symptoms in a multiple-symptom concept.7 Indeed, some studies
have suggested that physical and mental fatigue behave differently in
cancer patients.7 If physical and mental fatigue represent distinct
symptoms, it is plausible that they may have separate pathophysi-
ology and therefore may require different strategies for management
and assessment. More information is required regarding the un-
derlying pathophysiology of cancer-related fatigue. For example,
physical fatigue may have a peripheral or central origin in neuro-
muscular disorders but not in cancer-related fatigue.8
Epidemiology of Fatigue
In the general population, symptoms of fatigue have been re-
ported by approximately a quarter to a third of those surveyed.9,10
Cancer-related fatigue can emerge before, during, and after treat-
ment. Up to 40% of patients report fatigue at diagnosis of cancer,
although treatment-associated fatigue is experienced by the majority
of patients with cancer (90% of patients receiving radiotherapy and
80% of patients receiving chemotherapy).1 Reported rates of post-
treatment fatigue vary (17%-53%) depending on the criteria used
for assessment.1 Fatigue is also a common symptom in patients with
CRC, particularly in those undergoing treatment (46% of patients
experienced moderate to severe fatigue during treatment, while fa-
tigue persisted in 27% of survivors).11 Table 1 provides an overview
of the grades of fatigue experienced by CRC patients undergoing
treatment compared to survivors.
When considering specific treatments in metastatic CRC, grade 3
or 4 fatigue is commonly associated with chemotherapeutic regi-
mens compared to biologic agents provided alone, although caution
should be exercised when comparing data across studies (Table 2).
In addition, it is well established that symptomatic toxicities, such as
fatigue, are underreported in studied cohorts, thus suggesting that
these incidences are likely to be higher than documented.2,22
Impact of Fatigue
Studies have shown that fatigue can have a marked impact on
activities of daily living in patients with cancer, directly affecting
their QoL.11,23 In addition, patients with CRC who experienced
continuous fatigue are at a higher risk of death than patients who
did not experience fatigue (2.56 increased risk of death).24 Fatigue
in cancer patients who had previously undergone chemotherapy
made it harder to take part in social activities and to carry out
cognitive tasks.25 Fatigue also had a substantial impact on patients’Clinical Colorectal Cancer December 2017working life, with 75% of 177 patients reporting having changed
their employment status because of their fatigue,25 thus suggesting
an economic burden of this symptom. A multicenter study
including CRC patients in addition to breast, prostate, and lung
cancer patients showed that increased fatigue severity was associated
Figure 1 Factors Associated With Cancer-Related Fatigue
Reproduced With Permission From Koornstra et al (2014).1
Matti Aapro et alwith greater interference with functioning as assessed by the MD
Anderson Symptom Inventory (MDASI). This included an impact
on relationships, mood, enjoyment of life, walking, general activity,
and work.11 Fatigue and depression frequently occur together in
cancer patients and these symptoms may act synergistically, so it is
important to address both whenever possible.26 This is made more
complex because fatigue is one criterion for diagnosing depression.
Therefore, assessment tools have been developed that omit somatic
symptoms, including fatigue, from their criteria.26 The presence of
fatigue is often associated with depression in cancer patients
(including in CRC patients); however, the casual relationship be-
tween the two is unclear.11,12 Furthermore, pain, sleep disturbance,
and nutritional deficits or imbalance have all been shown to
contribute to or be associated with cancer-related fatigue.27 In
addition, because fatigue is a criterion of depression, the Patient
Help Questionnaire-2 (PHQ-2) is used to screen fatigued patients
for possible depression,28 which will be treated specifically.
These data highlight the importance of accurate assessment and
management of cancer-related fatigue in patients, as under-
recognition and undertreatment may ultimately affect clinical out-
comes as well as the patient’s QoL.
Etiology (or Pathophysiology) of
Fatigue
Fatigue can arise from the cancer itself, from treatment, or from a
variety of syndromes and concurrent conditions associated with the
malignancy.1 Figure 1 summarizes the numerous factors that can
contribute to fatigue in cancer patients.It is likely that the causes of cancer-related fatigue are multifac-
torial. The possible causes include comorbidities, medical compli-
cations such as anemia, side effects of other medications, and a range
of physical and psychologic factors. A recent prospective
caseecontrol study investigated the factors associated with fatigue in
breast cancer survivors. While chemotherapy was a major contrib-
utor to fatigue during patient treatment, lifestyle factors, including
physical inactivity and obesity, were associated with persistent
physical fatigue. Psychologic conditions relating to depression and
pain were also associated with long-term fatigue.29
A number of underlying mechanisms have been proposed to
drive cancer-related fatigue. For example, a substantial amount of
evidence has implicated inflammatory cytokines in cancer-related
fatigue, which has been reviewed in detail elsewhere.30 It has been
hypothesized that cancer cells and treatments, as well as other fac-
tors, can activate cytokine release, which subsequently mediates
changes in the central nervous system that generate symptoms of
fatigue. It has been shown that the administration of some cytotoxic
chemotherapies can activate the release of pro-inflammatory cyto-
kines.31 For example, treatment for CRC with raltitrexed or car-
mofur was associated with serum increases in C-reactive protein
(CRP) compared to pretreatment levels.32
The tumor can also release cytokines before treatment. Tumors
are able to remodel the stroma and create a permissive microenvi-
ronment for their progression. They secrete factors that activate
stromal cells and/or recruit inflammatory cells. Soluble factors
including cytokines that control survival, differentiation, and
growth of tumor cells (and therefore assist tumor promotion andClinical Colorectal Cancer December 2017 - 277
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278 -progression) are secreted by cells in the microenvironment.33 The
pro-inflammatory cytokines tumor necrosis factor (TNF) alpha and
interleukin (IL)-6 are secreted by adipocytes and adipose tissue,
respectively, with increased secretion in obese subjects.34,35 Sub-
cutaneous and abdominal visceral fat mass increases in volume
within months after chemotherapeutic treatment in metastatic but
otherwise healthy testicular cancer patients.36 Cytokine absolute
levels also increase in CRC; however, there are additional variations
in the relative cytokine levels signifying an alteration in the balance
of the immune system.37 IL-2 treatment-related adverse effects have
been reported in patients including fatigue, decreased energy, and
anorexia.38
Furthermore, the development of fatigue is associated with the
production of inflammatory cytokines in cancer patients undergoing
treatment. In patients with regional, locally advanced CRC or
esophageal cancer undergoing chemoradiation, fatigue was the most
severe symptom experienced by patients at the start of therapy ac-
cording to the MDASI. A significant association was identified
between the development of fatigue and an increased blood con-
centration of the inflammatory marker soluble receptor 1 for tumor
necrosis factor (sTNF-R1). Higher concentrations of IL-6 and
sTNF-R1 were associated with greater fatigue severity compared to
lower concentrations. The link between cytokines and cancer-
related fatigue was independent of cancer type, cancer stage, body
mass index, age, sex, and previous chemotherapy.39 A similar study
from the same research group also found an association between
increased levels of sTNF-R1 and greater cancer-related fatigue in
patients with locally advanced nonesmall-cell lung cancer.39 More
research has been conducted in patients with cancers other than
CRC, with the majority of substantiating evidence linking inflam-
matory cytokines with fatigue coming from breast cancer studies.
Increased levels of IL-6 were associated with greater fatigue in breast
cancer patients undergoing chemotherapy.40 Higher levels of the
inflammatory markers CRP and IL-1 receptor antagonist were
associated with greater fatigue in patients with breast or prostate
cancer.41
De Sanctis and colleagues42 investigated the relationship between
pro-inflammatory cytokines, fatigue, and erythema of breast skin
during radiotherapy in patients with breast cancer. Seven (17.5%)
of the 40 patients had cancer-related fatigue. The authors suggested
that the relatively low incidence of cancer-related fatigue was
because of the strict diagnostic criteria used; patients were not
diagnosed with cancer-related fatigue if they presented with
concomitant depression or anxiety. Interestingly, levels of IL-1b, IL-
2, IL-6, and TNF-a were increased 4 weeks after radiotherapy in
breast cancer patients compared to pretreatment levels.42 There also
appeared to be a significant influence (according to Heckman 2-step
analysis) of erythema on the production of pro-inflammatory bio-
markers, which in turn was positively associated with fatigue.42
Increased plasma levels of IL-6 have also been associated with
greater fatigue severity in patients with multiple myeloma after
undergoing autologous stem cell transplantation.43 Serum levels of
soluble IL-6 receptor were inversely related with fatigue in this
population.43
Some studies have also demonstrated a correlation between the
concentration of inflammatory markers and fatigue in patients with
ovarian cancer or acute myeloid leukemia before treatment forClinical Colorectal Cancer December 2017cancer has started.44,45 In patients with peritoneal carcinomatosis,
fatigue assessed before surgery was associated with increased levels of
IL-6 and CRP.46 Drugs, including chemotherapy, steroids, and
immunosuppressants, are routinely withheld for approximately 4
weeks before surgery for peritoneal carcinomatosis, suggesting that
cytokine production and fatigue were independent of cancer treat-
ment.46 However, the treatment histories of patients included in the
study were unclear. In a study of patients that had metastatic CRC
and “dampened” rest/activity patterns, fatigue and cytokines were
higher before treatment with chemotherapy compared to those that
had normal rest/activity patterns.47 Patients who had fatigue scores
of over 33% (measured by European Organization for Research and
Treatment of Cancer [EORTC] QLQ-C30) had higher trans-
forming growth factor-a (TGF-a) levels compared to patients who
were not fatigued. There was a positive correlation between TGF-a
serum concentration and fatigue score.47 In contrast, a 2014 study
of 291 early-stage CRC patients, 72 metastatic CRC patients, and
72 healthy controls failed to demonstrate an association after
diagnosis between pretreatment cancer-related fatigue and inflam-
matory cytokines.48 Fatigue, assessed by the Functional Assessment
of Cancer TherapieseFatigue (FACT-F) subscale, was reported by
52% of early-stage patients and 26% of healthy controls (P < .001),
with 68% of patients with metastatic disease feeling fatigued. While
median levels of most of the cytokines tested for was higher in
cancer patients overall, no association was found between cytokine
and fatigue levels. Median hemoglobin levels were lower in early-
stage CRC patients compared to healthy controls (131 g/L vs.
142 g/L; P < .001), and lower hemoglobin was also weakly asso-
ciated with greater fatigue levels.48
In cancer patients, cytokines and systemic inflammatory response
have been implicated in the development of both sarcopenia, which
is characterized by a loss of muscle and function and cachexia, which
is a multifactorial and complex syndrome affecting energy meta-
bolism, skeletal muscle, adipose tissue, and the metabolism of
protein lipid and glucose in cancer patients.49 Both sarcopenia and
cachexia are interwoven with the development of fatigue in cancer
patients. For example, there is a correlation between cancer-related
fatigue and midarm circumference.50,51 In a study of 84 patients
with inoperable gastrointestinal cancer (n ¼ 68) or nonesmall-cell
lung cancer (n ¼ 16), higher cancer-related fatigue was correlated
with a loss of muscle mass and strength. Fatigue, as measured by the
Brief Fatigue Inventory (BFI), was associated with poor hand grip
and quadriceps strength, and low skeletal muscle mass index.52 In
addition, sarcopenia is a negative prognostic factor for survival in
CRC patients who have undergone resection53 and predicts post-
operative infections and longer hospital stays.54 In esophagogastric
cancer, sarcopenia was predictive of dose-limiting toxicity (odds
ratio [OR], 2.95; 95% confidence interval [CI], 1.23 to 7.09; P ¼
.0015).55
Male hypogonadism is an important contributor to the patho-
physiology of both sarcopenia and cachexia in advanced cancer
patients.49 In a recent study, 100 men with advanced lung and
gastrointestinal cancer showed that 76% of patients presented with
male hypogonadism due to low free testosterone levels (< 31.2
pmol/L).56 In this cohort, male hypogonadism was independently
associated with lower albumin (3.8 g/L; 95% CI, 6.8 to 0.8),
muscle strength (11.7 lb; 95% CI, 20.4 to 3.0), and mass in
Matti Aapro et alupper limbs (0.8 kg; 95% CI, 1.4 to 0.1), overall performance
status (Eastern Cooperative Oncology Group Performance Scale,
0.6; 95% CI, 0.1 to 1.1), cancer-related fatigue (BFI, 16.7; 95% CI,
2.0 to 31.3), and overall QoL (McGill Quality of Life Question-
naire [MQoL] total score 1.42; 95% CI, 2.5 to 0.3).
These data highlight the importance of accurate screening and
assessment of cancer-related fatigue and its pathophysiologic
mechanisms. Either the reversal of these mechanisms or the pallia-
tion of fatigue may ultimately affect clinical outcomes as well as
CRC patients’ QoL.
Diagnosis of Fatigue
The EAPC has developed an algorithm for the diagnosis of fa-
tigue in cancer patients,4 which involves initial screening of patients
for fatigue in the clinic, where a single question inquiring how the
patient feels is asked (eg, “Do you feel unusually tired or weak?,”
“How weak are you?,” or “How tired are you?”). The NCCN
recommends screening every patient for fatigue at regular intervals
using a single-item scale before a more in-depth assessment of fa-
tigue.5 Once it has been established that patients are experiencing
fatigue, a more thorough assessment by questionnaire or interview
can be performed along with physical and laboratory evaluations,
compiled together with a complete overview of their medical
history.57
The interview should focus on determining 3 different major
symptoms that can characterize fatigue in cancer patients: (1) easy
tiring and reduced capacity to maintain performance (often associ-
ated with anemia or muscular demise); (2) generalized weakness
often reported as lack of stamina or anticipatory sensation of diffi-
culties in initiating activities; and (3) mental fatigue (often defined
as “total fatigue”), characterized by presence of impaired mental
concentration, loss of memory, and emotional lability.58
A number of different assessment tools may be used. General
cancer QoL questionnaires (such as the European Organisation for
Research and Treatment of Cancer QoL questionnaire [EORTC
QLQ-C30]) assess the overall well-being of the patient, with specific
questions that relate to cancer- or treatment-related symptoms.
There are also tools that are specific to fatigue assessment in patients
(BFI, Multidimensional Fatigue Symptom Inventory [MFSI],
Multidimensional Fatigue Inventory [MFI-20], the Piper fatigue
scale, and Visual Analogue Scale to Evaluate Fatigue Severity [VAS-
F]), as well as those that specifically look at cancer-related fatigue
(Functional Assessment of Cancer Therapy Fatigue Instrument
[FACIT-F] and Schwartz cancer fatigue scale). In terms of simplicity
and ease of use, the VAS-F and BFI are valuable tools, and the
FACIT-F and MFSI have been validated in a number of languages.
Other tools exist that do not provide as much detail; these are rarely
used in clinical trials.57
Some tools are unidimensional (BFI) and others multidimen-
sional (MFSI; EORTC QLQ-FA13) explorations of the physical,
cognitive, and emotional aspects of cancer-related fatigue. It is
important to select a tool that provides enough detail to obtain
useful information on the scope and severity of fatigue while being
simple and easy for patients to complete. These questionnaires can
take a long time to complete and evaluate, so patients are often
asked to rate their fatigue on a single-item scale as a screening
procedure. Typically, on a numerical rating from 0 to 10, scores of 4or above instigate the use of more complex questionnaires exploring
different dimensions of fatigue (either separately in a series of
questionnaires or in a single multidimensional inventory).5,59
As outlined, a detailed laboratory assessment should also be
performed for differential diagnosis of fatigue, including indicators
of anemia (hemoglobin, transferrin, ferritin, iron, erythropoietin,
transferrin saturation), electrolyte dysregulation (sodium, potas-
sium, calcium, magnesium, phosphate), organ dysfunction (creati-
nine, bilirubin), hypothyroidism (thyroid-stimulating hormone, free
T3 and T4), infection (white blood cell count, C-reactive protein),
hormone imbalance (adrenocorticotropic hormone, cortisol, free
testosterone, melatonin), vitamin deficiency (B1, B6, B12), and
disrupted cytokine load (markers for increased cytokine load might
be better suited than cytokines themselves).4 Nutritional markers
should also be considered, such as albumin and prealbumin.60
Management of Fatigue
Approaches to managing fatigue in people with cancer have been
proposed in the NCCN guidelines5 and by the EAPC. A practical
guide to managing cancer-related fatigue has recently been pub-
lished by Koornstra and colleagues,1 in which a treatment algorithm
was proposed that includes preventative measures as well as psy-
chosocial support and pharmacologic and nonpharmacologic
interventions.
Across the different recommendations, it is agreed that health
care professionals should educate their patients on fatigue, including
causes and potential self-management strategies. Proactive discus-
sion and appraisal of fatigue should be part of clinical evaluations,
and patients should be encouraged to monitor fatigue between
appointments, particularly those who did not report it at
screening.1,61 In these discussions, patients should be made aware of
the likelihood of fatigue with their disease and treatment, and how
this may affect their daily life. It is also important to emphasize the
benefits of early reporting of fatigue to allow for rapid and effective
management.61 Patients should be encouraged to remain positive
and resourceful and to find a daily routine that conserves energy by
balancing activity and rest.
Although not specifically recommended by the guidelines, non-
pharmacologic interventions include psychosocial support (eg,
counseling, psychotherapy, cognitive behavioral therapy), sleep
therapy, and complementary therapies (eg, relaxation techniques,
massage, herbal remedies [eg, American ginseng], yoga, acupunc-
ture).1 Additional support from dieticians, physiotherapists, and
occupational therapists may also be beneficial so patients maintain a
healthy diet and lifestyle that helps them to cope with their fatigue.1
Exercise is also an important factor in fatigue management.
Most patients with fatigue will require symptomatic treatment
using a combination of pharmacologic and nonpharmacologic ap-
proaches. For example, correcting anemia and electrolyte distur-
bances; managing comorbidities; alleviating pain, emotional distress,
and sleep disturbances; and addressing dehydration can help
improve fatigue. If the fatigue seems to arise as a side effect of
therapy, then a change to the treatment regimen might be appro-
priate; however, care must be taken not to compromise clinical
outcomes, so this approach should only be used if the fatigue is
severe and unresponsive to other management approaches.1 The
causes of fatigue differ markedly between patients and can vary overClinical Colorectal Cancer December 2017 - 279
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280 -the course of the disease; as such, treatment needs to be individu-
alized and reviewed regularly.1
Pharmacologic Interventions for
Cancer-Related Fatigue
Relatively few therapeutic agents have been shown to alleviate
fatigue in randomized controlled trials.62 The NCCN recommen-
dations to use psychostimulants as active treatment is not widely
followed outside of the United States, with recent publications
recommending that their use be reevaluated and perhaps reserved
for fatigue in advanced disease only.63,64 Data from a placebo-
controlled trial of modafinil in lung cancer patients found no ef-
fect on cancer-related fatigue and was associated with a clinically
significant placebo effect, questioning its use at all in this setting.65
A previous multicenter, double-blind, randomized trial found that
modafinil only improved symptoms in severely fatigued cancer pa-
tients undergoing chemotherapy and showed no benefit for those
with mild or moderate fatigue.66 The heterogeneity of patients with
cancer-related fatigue and the complexity of designing rigorous
studies in this setting may explain the disparity in results.62 A meta-
analysis of 27 randomized controlled trials investigating drug
interventions for cancer-related fatigue found that there may be
evidence for methylphenidate, a psychostimulant, being superior to
placebo.67 The meta-analysis included 2 studies of methylphenidate
(n ¼ 264), which demonstrated a greater change in FACT-F score
versus placebo (0.30; 95% CI, 0.54 to 0.05; P ¼ .02).67
Authors of the meta-analysis noted that the effect was not large
and that 1 of the 2 studies included had not demonstrated a benefit
on fatigue over placebo. In an updated review in 2010, including 2
further trials of methylphenidate and another of dexamphetamine,
psychostimulants again demonstrated a small but significant
improvement in fatigue scores versus placebo (n ¼ 426). It was
concluded that large-scale trials of methylphenidate are required to
validate these preliminary results.68 A recent study by Del Fabbro
et al69 investigating the effect of testosterone replacement on fatigue
in hypogonadal men with advanced cancer by the FACIT-F scale
showed significant improvement of fatigue only after 10 weeks of
treatment. However, the same authors concluded that larger studies
of longer duration were warranted before routine testosterone
replacement could be recommended. Table 3 summarizes some of
the studies to date assessing pharmacologic interventions for cancer-
related fatigue. For the purposes of this review, we have not
included treatment for anemia in Table 3, which can be argued to
be a reversible contributing factor.
Although some of the pharmacologic interventions in Table 3
have demonstrated efficacy in clinical trials of cancer-related fa-
tigue, only a few are currently recommended by the NCCN.5
Considering methylphenidate after ruling out other causes of fa-
tigue is recommended by the NCCN. However, it is stated that its
use remains investigational and that optimal dosing has yet to be
established.5 In addition, several studies have shown the effective-
ness of corticosteroids (eg, dexamethasone) in providing short-term
relief for fatigue and improving QoL. However, long-term toxicity
restricts their use to specific patient groups, especially given their
catabolic effects on muscle, with the NCCN recommending
considering corticosteroids as an intervention for cancer-related fa-
tigue in the palliative setting.5Clinical Colorectal Cancer December 2017Several interventions in Table 3 have shown promising pre-
liminary results that require further assessment before they can be
considered for inclusion in clinical guidelines. Currently etanercept,
testosterone, guarana, and sertraline are not mentioned in the
NCCN guidelines for cancer-related fatigue. However, the positive
results from small trials of these interventions warrant further
investigation. There may also be some preliminary data to support
the use of ginseng. In a double-blind study of 364 cancer survivors
with fatigue, 2000 mg of ginseng per day resulted in greater changes
in MFSI score at 8 weeks versus placebo (change in MFSI ¼ 20,
SD ¼ 27, vs. 10.3, SD ¼ 26.1).77 A greater benefit was derived in
those undergoing active treatment. Other dietary supplements were
excluded from the current NCCN guidelines because of mixed re-
sults.5 While coenzyme Q10 and L-carnitine have shown no benefit
when assessed alone,76,78 one small study found an improvement
when they were combined with other supplements.79
In patients where fatigue arises as a side effect of treatment,
experience from clinical trials indicates that it can be effectively
managed with treatment breaks, dose adjustments, and appropriate
intervention.81 Therefore, early assessment and frequent monitoring
of fatigue should be part of the treatment evaluation.82
Effect of Exercise on Fatigue
It is known that physical activity produces numerous beneficial
physiologic changes on markers of physical performance that may
help to counteract some of the causes of fatigue, such as increasing
hemoglobin levels, cardiorespiratory fitness and capacity, muscle
mass, and strength.83
In addition, vigorous physical activity limits the loss of sarcopenia
and skeletal muscle oxidative capacity in early-stage disease.84 The
typical response to high levels of physical activity involves the
secretion of a regular sequence of anti-inflammatory and pro-
inflammatory cytokines, with IL-6 playing a major role.85 IL-6
induces modifications including insulin resistance in adipose tis-
sue,86 and it profoundly decreases muscle protein turnover in
healthy individuals.87 Adipose tissue is able to produce various cy-
tokines, including IL-6, that may modulate glucose homeostasis,88
and baseline levels of IL-6 are required to modulate lipid homeo-
stasis.89 In studies of healthy and obese participants, it appears that
exercise programs reduce TNF-a levels and may increase muscle-
derived IL-6.90
A meta-analysis of 7 observational studies assessed the effect of
physical activity—initiated before or after diagnosis of CRC—on
overall survival and cancer-specific survival. Increased levels of
physical activity after diagnosis of CRC were associated with a
greater-specific survival compared to low levels of physical activity
(hazard ratio, 0.61; 95% CI, 0.44 to 0.86; P < .001). Higher levels
of activity after diagnosis were also associated with significantly
improved overall survival compared to lower levels of activity
(hazard ratio, 0.62; 95% CI, 0.54 to 0.71; P< .001).91 The authors
of the study suggested that the impact of physical activity on overall
survival was likely an expected product of the benefits of exercise on
cardiovascular health.91
The results of the studies provide initial support for incorporating
a program of exercise into the treatment of CRC patients based on
improved outcomes.91 However, exactly what can be inferred from
the studies as to necessary intensity or the design of an exercise
Table 3 Pharmacologic Interventions Assessed for Efficacy in Cancer-Related Fatiguea











84 Dexamethasone (n ¼ 43) 4 mg or
placebo (n ¼ 41) orally twice daily
FACIT-F Significantly higher mean  SD
improvement in FACIT-F at day 15
in the dexamethasone group vs.
placebo (9  10.3 vs. 3.1  9.59;
P ¼ .008)




154 Dexmethylphenidate 5 mg (n ¼ 76)
placebo or (n ¼ 78) twice daily
FACIT-F Significant improvement in FACIT-F
at week 8 for dexmethylphenidate
group vs. placebo (P ¼ .02)
Methylphenidate Bruera 201372 Randomized,
placebo-controlled,
phase 2 trial
141 Methylphenidate dose 5 mg every 2
hours as needed up to 20 mg daily
or placebo
FACIT-F No significant difference in the median
improvement in FACIT-F fatigue for
methylphenidate vs. placebo (5.5 vs.
6.0, P ¼ .69)
Methylphenidate Moraska 201073 Randomized,
placebo-controlled,
phase 2 trial
148 Methylphenidate (n ¼ 74) target
dose, 54 mg daily or placebo
(n ¼ 74)







867 Oral modafinil 200 mg daily
(n ¼ 315) or a placebo (n ¼ 316)
BFI Significant interaction between
modafinil and baseline fatigue
(ANCOVA; P ¼ .017); only patients
with severe baseline fatigue benefited
Etanercept Monk 200674 Randomized,
controlled pilot
12 Etanercept 25 mg (n ¼ 6)
subcutaneously twice weekly or
placebo
FSI Etanercept group reported less
fatigue vs. no etanercept (P <.001)




189 Sertraline 50 mg (n ¼ 95), or
placebo (n ¼ 94), once daily
FACT-F No significant effect




376 Oral L-carnitine 2 g/d (n ¼ 189) or
placebo (n ¼ 187)
BFI No significant difference between
groups (P ¼ .57)




364 Ginseng 2000 mg (n ¼ 183) or
placebo (n ¼ 181)
MFSI-SF Significant difference at 8 weeks
for ginseng with change in MFSI-SF
of 20 (SD ¼ 27) group vs. 10.3
(SD ¼ 26.1) for placebo (P ¼ .003)
Coenzyme Q10 Lesser 201378 Randomized,
placebo-controlled
trial
236 300 mg oral coenzyme Q10 þ 300
IU vitamin E (n ¼ 122) or placebo
300 IU vitamin E (n ¼ 114)
POMS-F;
FACIT-F









57 Oral Inner Power once daily for 21
days þ regular care (n ¼ 28) or




Changes in worst level of fatigue and







75 50 mg oral guarana twice daily
(n ¼ 32) or placebo (n ¼ 43)
FACIT-F;
FACT-ES; BFI
Improved FACIT-F; FACT-ES; BFI







29 150-200 mg intramuscular
testosterone (n ¼ 13) or placebo
(n ¼ 16) every 2 weeks
FACIT-F Improved FACIT-F not at day 29
but only at day 79 (P ¼ .03)
Abbreviations: ANCOVA ¼ analysis of covariance; BFI ¼ Brief Fatigue Inventory; FACIT-F ¼ Functional Assessment of Chronic IllnesseFatigue subscale; FACT-ES ¼ Functional Assessment of
Chronic Illness TherapyeEndocrine Symptoms; FSI ¼ Fatigue Symptom Inventory; FSS ¼ Fatigue Severity Scale; MFSI-SF ¼ Multidimensional Fatigue Symptom InventoryeShort Form; POMS-F ¼
Profile of Moods States Fatigue subscale.
aThis list is not exhaustive for treatments that have been assessed in cancer-related fatigue or number of clinical studies for each treatment.
Matti Aapro et alprogram is unclear. Three of the studies included in the meta-
analysis had a high-activity cutoff of  18 MET (metabolic
equivalent) hours per week.91 Prospective randomized controlled
trials investigating the impact of exercise in CRC are limited. A
long-term prospective study, the Colon Health and Life-Long Ex-
ercise Change (CHALLENGE) study, is currently underway to
assess the effects of exercise on disease-free survival in patients with(predominately stage III) CRC who have completed adjuvant
chemotherapy over the last 2 to 6 months.92 This study will, we
hope, provide a clearer picture of the impact of exercise on out-
comes in CRC. Furthermore, cancer-related fatigue as measured by
the FACT-F subscale is a secondary end point for the study.
Clinical studies that have assessed the effect of physical exercise
on levels of fatigue and evidence show that aerobic or resistanceClinical Colorectal Cancer December 2017 - 281
Table 4 Relative and Absolute Contraindications to Exercise
Programs
Relative Contraindications
 Recent weight gain (>2 kg during the 3 days preceding exercise).
 Decrease in systolic BP during exercise.
 NYHA class IV cardiac status.
 Ventricular arrhythmia at rest or during exercise.
 Supine cardiac frequency 100 beats/minute.
 Neurologic toxicity greater than grade 2.
 Asymptomatic central neurologic lesions.
 Asymptomatic bone metastases.
Absolute Contraindications
 Progressive increase in dyspnea at rest or during exercise for 3-5
days preceding exercise.
 Low-flow ischemia.
 Uncontrolled diabetes mellitus.
 Acute disease or fever.
 Recent embolism.
 Thrombophlebitis.
 Myocarditis or active pericarditis.
 Moderate to severe aortic stenosis.
 Valvulopathy requiring surgery.
 Myocardial infarction during 3 preceding weeks.
 Relapsing atrial fibrillation.
 Symptomatic central neurologic lesions.
 Hematologic toxicity: platelets <50,000/mm3, leucocytes
<1500/mm3, hemoglobin <8 g/dL.
 Symptomatic central neurologic lesions.
 Osteolytic or painful bone metastases.
Reasons to Stop or Modify Program
 Dyspnea or fatigue (14 on Borg scale).
 Exercise asthma crisis.
 Respiratory frequency >40/minute during exercise.
 Increase in crackles at auscultation.
 Hypotension (difference between systolic BP and diastolic
BP <10 mm Hg).
 Supraventricular or ventricular tachycardia during exercise.
 Paleness or confusion.
 Paraesthesias (platinum salts, taxanes, etc) may cause proprioceptive
alterations with increased risk of falls during PAS.
 Dermatoses, especially exudative dermatoses (postradiation, tyrosine
kinase inhibitors, 5-fluorouracil) with pain related to rubbing and risks of
wound or skin infection. Skin toxicity higher than grade 2.
Abbreviations: BP ¼ blood pressure; NYHA ¼ New York Heart Association.
Reproduced with permission from Bouillet et al (2015).104
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282 -exercise reduces fatigue and demonstrates beneficial effects in cancer
survivors and those receiving cancer treatment.83,93-97 In addition to
a reduction in fatigue itself, other benefits of exercise reported in
cancer patients include increased strength, reduced risk of relapse,
less discomfort during therapy, and improved mood, QoL, and
physical performance.98-100 In CRC patients, improved QoL,
improved anxiety, and disease-free survival have been reported in
patients who engaged in regular exercise compared to those who
were less physically active.99,101
In a meta-analysis of 44 randomized clinical trials, it was found
that exercise reduced fatigue in cancer survivors to a greater extent
than those receiving standard care (no exercise program—patients
maintained current activity). The trials investigated the impact of
various exercise interventions in survivors with various cancer types
(25 studies included breast cancer patients, while only 1 study
included CRC patients).94 A 2012 meta-analysis of 56 randomized
clinical trials (the majority in breast cancer) showed that improve-
ments in fatigue were greater in cancer patients undergoing an ex-
ercise program compared to a control intervention, with
improvements in fatigue observed after exercise either during cancer
treatment or after therapy.93
There have been few studies investigating the impact of exercise
in patients with CRC undergoing chemotherapy. One randomized
clinical trial of 66 adults assessed the impact of a home-based ex-
ercise program; improvements in fatigue, mobility, and sleep quality
in people with stage IV lung cancer or CRC compared to those
receiving usual care (not instructed to exercise) were observed.102
In a small study of 45 patients with CRC, a significant
improvement in fatigue was reported in those taking part in a su-
pervised exercise program when assessed as a subscale of the
EORTC QLC-C30 compared to usual care, although when assessed
by the Fatigue Symptom Inventory (FSI), the exercise program did
not have a significant impact on fatigue.103 In addition to the small
sample size, this discordance may be due to the severity of fatigue in
patients included in the study, as the authors noted that mean scores
of fatigue using FSI were on the borderline of being clinically
meaningful. Furthermore, after 3 months, patients with CRC who
followed the exercise program showed improvements in physical
and social functioning as well as pain.103
While regular physical activity is beneficial for patients with
cancer who experience fatigue, an exercise program may not be
appropriate for all patients, including those with thrombocyto-
penia, fever, or active infection; pain; bony metastases or spinal
instability; malnourishment; or orthopedic or rheumatic dis-
ease.82,83 However, in appropriately managed and monitored
patients with CRC, there appears to be provisional evidence that
exercise programs can have a positive impact on cancer-related
fatigue, QoL, and clinical outcomes. Physicians will need to
consider relative and absolute contraindications for an exercise
program, which have recently been reviewed in detail elsewhere
and are summarized in Table 4. More studies are needed to fully
establish the effects of exercise in the CRC patient population
specifically.
We suggest modifications to the current NCCN approaches to
managing fatigue in CRC patients, including an increased focus on
the recognized benefits of exercise and psychosocial interventions
(Figure 2).5Clinical Colorectal Cancer December 2017Conclusion
The literature suggests that fatigue may be common, with the
potential to compromise outcomes and well-being in people with
CRC. Fatigue associated with CRC has a complex etiology,
underscoring the importance of addressing factors that may
contribute to fatigue before reducing the dose of therapy. Emerging
evidence suggests that exercise may improve QoL and survival, and
therefore may help patients tolerate chemotherapy. This review
proposes a treatment algorithm that may help clinicians tackle fa-
tigue related to CRC.Acknowledgments
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Figure 2 Proposed Treatment Algorithm for Fatigue in Cancer Patients
Active treatment:
• Education: fatigue does not indicate 
disease progression 
• Assessment and monitoring of 
fatigue   
• Identification of contributing causes 
• Treatment of reversible factors 
• Behavioural measures including 
exercise programme of both 
endurance (walking, jogging or 
swimming) and resistance (light 
weights) exercise, at least 3 to 5 
hours of moderate activity / week 
(groups or individual) 
• Psychosocial interventions including 
cognitive behavioural therapy 
• Pharmacologic interventions: 
consider psychostimulants (i.e. 
methylphenidate) 
Post-treatment:
• Education: normal fatigue 
pattern during and after 
treatment 
• Assessment and monitoring of 
fatigue   
• Identification of contributing 
causes 
• Treatment of reversible factors 
• Behavioural measures including 
exercise programme with 
endurance and resistance 
exercise (groups or individual) 
• Psychosocial interventions 
including cognitive behavioural 
therapy 
• Pharmacologic interventions 
End-of-life:
• Education: fatigue as part of 
disease stage 
• Assessment and monitoring 
of fatigue   
• Identification of contributing 
causes 
• Treatment of reversible 
factors, if possible 
• Behavioural measures 
including optimised level of 
physical activity with careful 
consideration of constraints 
(individual) 
• Psychosocial interventions 
• Pharmacologic interventions: 
consider psychostimulants 






Education how to 
prevent fatigue
Before treatment: 
• Assessment and monitoring 
of fatigue   
• Identification of contributing 
causes (investigation of 
aetiology, blood tests, 
specific tests) 
• Treatment of reversible 
factors: optimise treatment 






treatment of hypogonadism 
in male patients.  
• Adapt specific anti-cancer 
treatment 
• Education 
4–10: Moderate to 
severe fatigue
Consider disease stage 
and oncological treatment 
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